Evidence map›Paper›PMID 40056910›Full record

ArticleCell reports. Medicine2025

Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson's disease.

Shijun Yan, Wenjing Zhang, Xinying Li, Suman Dutta, Andrew R Castle, Yiming Liu, Anis Sahoo, Chor Lai Lam, Nicholas J F Gatford, Michele T Hu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shijun YanNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Wenjing ZhangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, People's Republic of China.
Xinying LiDermatology Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Suman DuttaNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Andrew R CastleNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Yiming LiuSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, People's Republic of China.
Anis SahooNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Chor Lai LamNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Nicholas J F GatfordNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Michele T HuNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.
Chen-Zhong LiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, People's Republic of China.
Cheng JiangSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, People's Republic of China. Electronic address: jiangcheng@cuhk.edu.cn.
Bowen ShuDermatology Hospital, Southern Medical University, Guangzhou, People's Republic of China. Electronic address: shubw@scnu.edu.cn.
George K TofarisNuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK. Electronic address: george.tofaris@ndcn.ox.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate diagnosis of early Parkinson's disease requires platforms suitable for detecting minute amounts of neuronally derived biomarkers in the massive protein excess of easily accessible biofluids such as blood. Here, we describe an on-chip droplet-confined fluorescence reporting assay that identified α-synuclein on the membrane of L1CAM+ extracellular vesicles (EVs) immunocaptured from human serum and corroborate this finding by super-resolution direct stochastic optical reconstruction microscopy (dSTORM) microscopy. Using conditioned media from neuroblastoma cells expressing α-synuclein mutants or patient-derived induced pluripotent stem cell (iPSC) neurons with α-synuclein gene triplication, we found that association of α-synuclein with the L1CAM+ EV surface is increased under pathological conditions. Accordingly, this readout, as measured by the droplet-based assay, is an improved predictive biomarker in the prodromal phase (area under the receiver operating characteristic curve [AUC] = 0.93) or diagnostic biomarker in the clinical phase (AUC = 0.95) of Parkinson's disease. More broadly, our platform will simplify the assessment of EV membrane proteins and facilitate their application as diagnostic biomarkers across diverse clinical indications.

Indexed as

alpha-SynucleinExtracellular VesiclesParkinson DiseaseBiomarkersCell Line, TumorHumansInduced Pluripotent Stem CellsNeuronsalpha-SynucleinBiomarkersaggregationbiomarkerdroplet microfluidicsimmunoassayL1CAMneuronally derived extracellular vesiclesParkinson’s disease diagnosticsprodromalRBDα-synuclein

Identifiers

PMID40056910
PMCPMC11970385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.